Establishment Labs Holdings
Market Cap
US$409.6m
Last Updated
2019/09/22 00:35 UTC
Data Sources
Company Financials +
Executive Summary
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery.
Snowflake
Fundamentals
Limited growth with imperfect balance sheet.
Risks
- Establishment Labs Holdings has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has Establishment Labs Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-4.6%
ESTA
1.1%
US Medical Equipment
-0.6%
US Market
1 Year Return
-17.8%
ESTA
9.9%
US Medical Equipment
0.7%
US Market
ESTA underperformed the Medical Equipment industry which returned 9.9% over the past year.
ESTA underperformed the Market in United States of America which returned 0.6% over the past year.
Share holder returns
| ESTA | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.6% | 1.1% | -0.6% |
| 30 Day | -2.4% | 1.3% | 2.9% |
| 90 Day | -8.6% | 3.0% | 1.3% |
| 1 Year | -17.8%-17.8% | 10.8%9.9% | 2.9%0.7% |
| 3 Year | n/a | 70.1%64.9% | 44.6%35.2% |
| 5 Year | n/a | 138.9%111.8% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Establishment Labs Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Is Establishment Labs Holdings (NASDAQ:ESTA) Using Debt In A Risky Way?1 month ago | Simply Wall St
Trade Alert: The Chairman of the Board Of Establishment Labs Holdings Inc. (NASDAQ:ESTA), Nicholas Lewin, Has Just Spent US$54k Buying Shares1 month ago | Simply Wall St
Did Changing Sentiment Drive Establishment Labs Holdings's (NASDAQ:ESTA) Share Price Down By 15%?Valuation
Is Establishment Labs Holdings undervalued based on future cash flows and its price relative to the stock market?
7.61x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Establishment Labs Holdings to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Establishment Labs Holdings to establish if it is available at substantial discount.
Price Based on Earnings
Establishment Labs Holdings is loss making, we can't compare its value to the US Medical Equipment industry average.
Establishment Labs Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Establishment Labs Holdings, we can't assess if its growth is good value.
Price Based on Value of Assets
Establishment Labs Holdings is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Establishment Labs Holdings expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
8.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Establishment Labs Holdings's revenue is expected to grow significantly at over 20% yearly.
Establishment Labs Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
Establishment Labs Holdings's revenue growth is expected to exceed the United States of America market average.
Unable to compare Establishment Labs Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Establishment Labs Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Establishment Labs Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Establishment Labs Holdings performed over the past 5 years?
2.3%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Establishment Labs Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
Unable to compare Establishment Labs Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Establishment Labs Holdings's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Establishment Labs Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Establishment Labs Holdings has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Establishment Labs Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Establishment Labs Holdings's financial position?
Financial Position Analysis
Establishment Labs Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Establishment Labs Holdings's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Establishment Labs Holdings's level of debt (44%) compared to net worth is high (greater than 40%).
Unable to establish if Establishment Labs Holdings's debt level has increased without past 5-year debt data.
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 3.6x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Establishment Labs Holdings has less than a year of cash runway based on current free cash flow.
Establishment Labs Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.1% each year.
Next Steps
Dividend
What is Establishment Labs Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Establishment Labs Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Establishment Labs Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Establishment Labs Holdings has not reported any payouts.
Unable to verify if Establishment Labs Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Establishment Labs Holdings has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Establishment Labs Holdings's salary, the management and board of directors tenure and is there insider trading?
2.2yrs
Average management tenure
CEO
Juan Jose Chacon Quiros (47yo)
6.7yrs
Tenure
US$483,516
Compensation
Mr. Juan Jose Chacon Quiros founded Establishment Labs, S.A. in 2004 and has been a Chief Executive Officer and Executive Director of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chaco ...
CEO Compensation Analysis
Juan Jose's remuneration is lower than average for companies of similar size in United States of America.
Juan Jose's compensation has increased whilst company is loss making.
Management Age and Tenure
2.2yrs
Average Tenure
38yo
Average Age
The tenure for the Establishment Labs Holdings management team is about average.
Board Age and Tenure
3.6yrs
Average Tenure
61yo
Average Age
The tenure for the Establishment Labs Holdings board of directors is about average.
Insider Trading
More shares have been bought than sold by Establishment Labs Holdings individual insiders in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 1,000 |
| Max Price | US$20.00 |
| Entity | Company |
| Shares | 1,000 |
| Max Price | US$20.40 |
| Entity | Company |
| Shares | 1,000 |
| Max Price | US$20.00 |
| Entity | Company |
| Shares | 2,000 |
| Max Price | US$21.42 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 2,700 |
| Max Price | US$20.11 |
| Entity | Company |
| Shares | 3,000 |
| Max Price | US$22.15 |
| Entity | Company |
| Shares | 1,500 |
| Max Price | US$25.31 |
| Entity | Company |
| Shares | 2,500 |
| Max Price | US$25.58 |
Ownership Breakdown
Management Team
Juan Jose Chacon Quiros (47yo)
Founder
- Tenure: 6.7yrs
- Compensation: US$483.52k
Eddie De Oliveira (37yo)
Vice President of Sales
- Tenure: 0yrs
- Compensation: US$429.33k
Renee M. Gaeta (38yo)
Chief Financial Officer
- Tenure: 2.2yrs
- Compensation: US$374.21k
Jeremy Livianu (38yo)
General Counsel
- Tenure: 1.4yrs
Roberto De Mezerville (39yo)
Chief Technology Officer
- Tenure: 1.6yrs
Salvador Santos Dada (37yo)
Chief Operating Officer
- Tenure: 3.6yrs
- Compensation: US$234.23k
Board Members
Dennis Condon (70yo)
Director
- Tenure: 1.8yrs
- Compensation: US$21.41k
David Hung (61yo)
Director
- Tenure: 3.6yrs
- Compensation: US$19.59k
Lisa Colleran (61yo)
Director
- Tenure: 3.8yrs
- Compensation: US$24.60k
Hall Gersh (60yo)
Director
- Tenure: 0.3yrs
Nick Lewin (41yo)
Chairman of the Board
- Tenure: 1.8yrs
- Compensation: US$4.53m
Juan Jose Chacon Quiros (47yo)
Founder
- Tenure: 6.7yrs
- Compensation: US$483.52k
Ed Schutter (68yo)
Director
- Tenure: 3.7yrs
- Compensation: US$19.36k
Marcos Sforza
Member of Medical Advisory Board
- Tenure: 0yrs
Dennis Hammond
Member of Medical Advisory Board
- Tenure: 0yrs
Niamh Corduff
Member of Medical Advisory Board
- Tenure: 0yrs
Company Information
Establishment Labs Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Establishment Labs Holdings Inc.
- Ticker: ESTA
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$409.587m
- Shares outstanding: 20.50m
- Website: https://www.establishmentlabs.com
Number of Employees
Location
- Establishment Labs Holdings Inc.
- Buildings B15 and 25
- Coyol Free Zone
- Alajuela
- Costa Rica
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ESTA | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Jul 2018 |
| 3 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jul 2018 |
Biography
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silic ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/22 00:35 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.